Product Categories
Productos
1. COMMON NAME:
Ciprofloxacin Hydrochloride tablet
2. COMPOSITION:
The main ingredient of this product is ciprofloxacin hydrochloride.
3. INDICATIONS:
For susceptible bacteria: 1. Urinary and reproductive system infections, including simple, complex urinary tract infections, bacterial prostatitis, Neisseria gonorrhoeae urethritis, or cervicitis (including those caused by enzyme-producing strains). 2. Respiratory infections, including acute attacks of bronchial infections and lung infections caused by sensitive Gram-negative bacilli. 3. Gastrointestinal infections, caused by Shigella, Salmonella, Enterotoxigenic Escherichia coli, Hydrophila aeromonas, Vibrio parahaemolyticus, etc. 4. Typhoid fever. 5. Bone and joint infections. 6. Skin and soft tissue infections. 7. Systemic infections such as sepsis.
4. USAGE and DOSAGE:
Oral. (1) Usual dosage for adults: 0.5 ～ 1.5g (ie 2 ～ 6 tablets) per day, divided into 2 ～ 3 times. (2) Bone and joint infections: 1 to 1.5 g (ie 4 to 6 tablets) a day, divided into 2 to 3 times, and the course of treatment is 4 to 6 weeks or longer. (3) Pneumonia and skin and soft tissue infection: 1 to 1.5 g (ie 4 to 6 tablets) a day, divided into 2 to 3 times, and the course of treatment is 7 to 14 days. (4) Intestinal infection: 1g (4 tablets) a day, divided into 2 times, the course of treatment is 5-7 days. (5) typhoid fever: 1.5g (ie 6 tablets) a day, divided into 2 to 3 times, the course of treatment is 10 to 14 days. (6) Urinary tract infection: acute simple lower urinary tract infection, 0.5g (ie 2 tablets) a day, divided into two sessions, the course of treatment is 5-7 days; complex urinary tract infection, 1g (ie 4 tablets) a day , 2 times, 7 to 14 days. (7) Simple gonorrhea: 0.5 g (ie 2 tablets) by single oral administration.
5. PACKAGING:
10×10, 200boxes/ctn
6. PHARMACOLOGICAL CLASSIFICATION:
The second-generation antibiotics of quinolones
7. SHELF LIFE:
36 months
8. STORAGE:
Keep in a cool, dry place and protect from light.
Keep out of reach of children.
